Exploring the mechanism of YangXue QingNao Wan based on network pharmacology in the treatment of Alzheimer’s disease
It is clinical reported that YangXue QingNao Wan (YXQNW) combined with donepezil can significantly improve the cognitive function of AD patients. However, the mechanism is not clear. A network pharmacology approach was employed to predict the protein targets and affected pathways of YXQNW in the tre...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.942203/full |
| _version_ | 1811282687914147840 |
|---|---|
| author | Yuying Zhang Kaimin Guo Pengfei Zhang Mengying Zhang Xiaoqiang Li Shuiping Zhou Shuiping Zhou He Sun He Sun Wenjia Wang Hui Wang Hui Wang Yunhui Hu |
| author_facet | Yuying Zhang Kaimin Guo Pengfei Zhang Mengying Zhang Xiaoqiang Li Shuiping Zhou Shuiping Zhou He Sun He Sun Wenjia Wang Hui Wang Hui Wang Yunhui Hu |
| author_sort | Yuying Zhang |
| collection | DOAJ |
| description | It is clinical reported that YangXue QingNao Wan (YXQNW) combined with donepezil can significantly improve the cognitive function of AD patients. However, the mechanism is not clear. A network pharmacology approach was employed to predict the protein targets and affected pathways of YXQNW in the treatment of AD. Based on random walk evaluation, the correlation between YXQNW and AD was calculated; while a variety of AD clinical approved Western drugs were compared. The targets of YXQNW were enriched and analyzed by using the TSEA platform and MetaCore. We proved that the overall correlation between YXQNW and AD is equivalent to clinical Western drugs, but the mechanism of action is very different. Firstly, YXQNW may promote cerebral blood flow velocity by regulating platelet aggregation and the vasoconstriction/relaxation signal pathway, which has been verified by clinical meta-analysis. Secondly, YXQNW may promote Aβ degradation in the liver by modulating the abnormal glucose and lipid metabolisms via the adiponectin-dependent pathway, RXR/PPAR-dependent lipid metabolism signal pathway, and fatty acid synthase activity signal pathway. We also verified whether YXQNW indeed promoted Aβ degradation in hepatic stellate cells. This work provides a novel scientific basis for the mechanism of YXQNW in the treatment of AD. |
| first_indexed | 2024-04-13T01:57:03Z |
| format | Article |
| id | doaj.art-4ea89ae9c0e84651b1d6b1e7dcf11af0 |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-13T01:57:03Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-4ea89ae9c0e84651b1d6b1e7dcf11af02022-12-22T03:07:44ZengFrontiers Media S.A.Frontiers in Genetics1664-80212022-08-011310.3389/fgene.2022.942203942203Exploring the mechanism of YangXue QingNao Wan based on network pharmacology in the treatment of Alzheimer’s diseaseYuying Zhang0Kaimin Guo1Pengfei Zhang2Mengying Zhang3Xiaoqiang Li4Shuiping Zhou5Shuiping Zhou6He Sun7He Sun8Wenjia Wang9Hui Wang10Hui Wang11Yunhui Hu12Cloudphar Pharmaceuticals Co. Ltd., Shenzhen, ChinaCloudphar Pharmaceuticals Co. Ltd., Shenzhen, ChinaTianjin Pharmaceutical and Cosmetic Evaluation and Inspection Center, Tianjin, ChinaCloudphar Pharmaceuticals Co. Ltd., Shenzhen, ChinaCloudphar Pharmaceuticals Co. Ltd., Shenzhen, ChinaThe State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co. Ltd., Tianjin, ChinaTasly Pharmaceutical Group Co. Ltd., Tianjin, ChinaThe State Key Laboratory of Core Technology in Innovative Chinese Medicine, Tasly Academy, Tasly Holding Group Co. Ltd., Tianjin, ChinaTasly Pharmaceutical Group Co. Ltd., Tianjin, ChinaCloudphar Pharmaceuticals Co. Ltd., Shenzhen, ChinaKey Laboratory of Molecular Biophysics, Hebei Province, Institute of Biophysics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, ChinaKey Laboratory of Bioactive Materials Ministry of Education, School of Life Sciences, Nankai University, Tianjin, ChinaCloudphar Pharmaceuticals Co. Ltd., Shenzhen, ChinaIt is clinical reported that YangXue QingNao Wan (YXQNW) combined with donepezil can significantly improve the cognitive function of AD patients. However, the mechanism is not clear. A network pharmacology approach was employed to predict the protein targets and affected pathways of YXQNW in the treatment of AD. Based on random walk evaluation, the correlation between YXQNW and AD was calculated; while a variety of AD clinical approved Western drugs were compared. The targets of YXQNW were enriched and analyzed by using the TSEA platform and MetaCore. We proved that the overall correlation between YXQNW and AD is equivalent to clinical Western drugs, but the mechanism of action is very different. Firstly, YXQNW may promote cerebral blood flow velocity by regulating platelet aggregation and the vasoconstriction/relaxation signal pathway, which has been verified by clinical meta-analysis. Secondly, YXQNW may promote Aβ degradation in the liver by modulating the abnormal glucose and lipid metabolisms via the adiponectin-dependent pathway, RXR/PPAR-dependent lipid metabolism signal pathway, and fatty acid synthase activity signal pathway. We also verified whether YXQNW indeed promoted Aβ degradation in hepatic stellate cells. This work provides a novel scientific basis for the mechanism of YXQNW in the treatment of AD.https://www.frontiersin.org/articles/10.3389/fgene.2022.942203/fullYangXue QingNao Wan(YXQNW)Alzheimer’s diseasenetwork pharmacologycerebral blood flow (CBF)liver functiontraditional Chinese medicine (TCM) |
| spellingShingle | Yuying Zhang Kaimin Guo Pengfei Zhang Mengying Zhang Xiaoqiang Li Shuiping Zhou Shuiping Zhou He Sun He Sun Wenjia Wang Hui Wang Hui Wang Yunhui Hu Exploring the mechanism of YangXue QingNao Wan based on network pharmacology in the treatment of Alzheimer’s disease Frontiers in Genetics YangXue QingNao Wan(YXQNW) Alzheimer’s disease network pharmacology cerebral blood flow (CBF) liver function traditional Chinese medicine (TCM) |
| title | Exploring the mechanism of YangXue QingNao Wan based on network pharmacology in the treatment of Alzheimer’s disease |
| title_full | Exploring the mechanism of YangXue QingNao Wan based on network pharmacology in the treatment of Alzheimer’s disease |
| title_fullStr | Exploring the mechanism of YangXue QingNao Wan based on network pharmacology in the treatment of Alzheimer’s disease |
| title_full_unstemmed | Exploring the mechanism of YangXue QingNao Wan based on network pharmacology in the treatment of Alzheimer’s disease |
| title_short | Exploring the mechanism of YangXue QingNao Wan based on network pharmacology in the treatment of Alzheimer’s disease |
| title_sort | exploring the mechanism of yangxue qingnao wan based on network pharmacology in the treatment of alzheimer s disease |
| topic | YangXue QingNao Wan(YXQNW) Alzheimer’s disease network pharmacology cerebral blood flow (CBF) liver function traditional Chinese medicine (TCM) |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2022.942203/full |
| work_keys_str_mv | AT yuyingzhang exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease AT kaiminguo exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease AT pengfeizhang exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease AT mengyingzhang exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease AT xiaoqiangli exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease AT shuipingzhou exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease AT shuipingzhou exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease AT hesun exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease AT hesun exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease AT wenjiawang exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease AT huiwang exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease AT huiwang exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease AT yunhuihu exploringthemechanismofyangxueqingnaowanbasedonnetworkpharmacologyinthetreatmentofalzheimersdisease |